Get the Stockscreener App
4.48
4.43%
0.19
After Hours:
4.48
Onkure Therapeutics Inc stock is traded at $4.48, with a volume of 1.65M.
It is up +4.43% in the last 24 hours and up +45.45% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
See More
Previous Close:
$4.29
Open:
$4.33
24h Volume:
1.65M
Relative Volume:
4.65
Market Cap:
$180.97M
Revenue:
-
Net Income/Loss:
$-58.75M
P/E Ratio:
-1.0354
EPS:
-4.327
Net Cash Flow:
$-50.79M
1W Performance:
+5.41%
1M Performance:
+45.45%
6M Performance:
+44.05%
1Y Performance:
+85.12%
1-Day Range:
$4.175
$4.50
1-Week Range:
$4.015
$4.545
52-Week Range:
$1.91
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.48 | 173.30M | 0 | -58.75M | -50.79M | -4.327 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
Onkure Therapeutics Inc (OKUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Onkure Therapeutics Inc (OKUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Onkure Therapeutics Inc (OKUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Onkure Therapeutics Inc (OKUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKUR Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Pipeline - newsline.com
Onkure Therapeutics Inc (OKUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKUR Q1 2026 Earnings: EPS Miss by 46.55% Signals Aggressive Pipeline InvestmentEarnings Revision Upgrade - newsline.com
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
OnKure Therapeutics (OKUR) director receives 7,650 stock options grant - Stock Titan
OnKure Therapeutics (OKUR) director awarded 1,275 stock options at $4.30 strike - Stock Titan
Director at OnKure (NASDAQ: OKUR) receives 7,650 stock options - Stock Titan
OnKure (OKUR) awards director 7,650 stock options at $4.30 - Stock Titan
OnKure (OKUR) director receives 7,650 options at $4.30 strike - Stock Titan
OnKure (OKUR) director awarded 7,650 stock options at $4.30 strike - Stock Titan
Onkure Therapeutics patents new PI3Kα mutant inhibitors - BioWorld News
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageSlow Growth Warning - newsline.com
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan - The Globe and Mail
OnKure (NASDAQ: OKUR) holders back equity plan changes and board slate - Stock Titan
OnKure Therapeutics (OKUR) Holds Steady Near Support: Can $4.43 Resistance Be Breached?Breakout Confirmation - newsline.com
OKUR Q1 2026 Earnings: EPS Miss of 46.6% Highlights Early-Stage R&D CostsGuidance Upgrade Report - thelegaladvocate.com
OnKure Therapeutics (OKUR) Advances 2.55% as Stock Holds Above Key SupportBollinger Expansion - The Legal Advocate
OKUR Q1 2026 Earnings: Wider EPS Loss Underscores Heavy R&D Investment as Pre-Revenue Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OKUR Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEarnings Stability Report - The Legal Advocate
OnKure Therapeutics Inc. (OKUR) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineMargin Guidance - The Legal Advocate
Survey finds most Boulder residents satisfied with quality of life - BizWest
OnKure Therapeutics (OKUR) Surges 14% Amid Renewed Investor InterestMerger Arbitrage - Newser
OnKure Therapeutics (OKUR) Q1 2026 Earnings Miss: EPS $-1.11 vs $-0.76 ExpectedReal Trader Insights - Newser
OnKure Therapeutics (OKUR) Jumps +7.88% on Strong Momentum 2026-05-20Technical Analysis Picks - The Legal Advocate
ADAR1 entities and Daniel Schneeberger report 6.0% of OnKure (NASDAQ: OKUR) - Stock Titan
TradingKey - TradingKey
The long term thesis for OnKure Therapeutics (OKUR) in plain sight (Breakdown Watch) 2026-05-11Social Momentum Signals - newser.com
OnKure Therapeutics (OKUR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT) - The Globe and Mail
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
OnKure Therapeutics war chest nears $200M following spring stock sale - BizWest
OnKure Buy Rating Reiterated as Analyst Backs Pipeline Refocus, Strong Cash Position and Maintains $16 Price Target - TipRanks
Oppenheimer Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Onkure Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
OnKure (Nasdaq: OKUR) lifts cash to $192.1 million after raise - Stock Titan
OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan
OnKure Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
OnKure Therapeutics Reports First Quarter 2026 Financial Results - marketscreener.com
[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan
Aclarion reports cash runway to ops into late 2027 - BizWest
What date does OnKure Therapeutics, Inc.'s (OKUR) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN
OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):